Merck & Company Inc (MRK)vsPhibro Animal Health Corporation (PAHC)
MRK
Merck & Company Inc
$146.73
-0.14%
HEALTHCARE · Cap: $368.89B
PAHC
Phibro Animal Health Corporation
$32.96
-6.89%
HEALTHCARE · Cap: $1.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4338% more annual revenue ($67.38B vs $1.52B). PAHC leads profitability with a 6.6% profit margin vs 3.6%. PAHC appears more attractively valued with a PEG of 1.68. PAHC earns a higher WallStSmart Score of 60/100 (C+).
MRK
Hold44
out of 100
Grade: D
PAHC
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.73
$61.86 premium
Margin of Safety
-9.1%
Fair Value
$47.21
Current Price
$32.96
$14.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Earnings expanding 24.6% YoY
Areas to Watch
Trading at 8.6x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Expensive relative to growth rate
4.8% revenue growth
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Revenue Growth, Market Cap. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
PAHC carries more volatility with a beta of 0.42 — expect wider price swings.
PAHC is growing revenue faster at 4.8% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PAHC scores higher overall (60/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?